Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinsonâ€™s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	ILA 267.00	+0.19%	4,800
10/09/26	ILA 266.50	-0.67%	92,607
09/09/26	ILA 268.30	+1.55%	104,441
08/09/26	ILA 264.20	-6.15%	181,863
07/09/26	ILA 281.50	-6.07%	199,855

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed TEL AVIV STOCK EXCHANGE 12:42:40 14/09/2026 +03			5-day change	1st Jan Change
267.00 ^ILa	+0.19%		-5.15%	-51.53%

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI

Market Cap	80.79M 0 26.66M 22.97M 21.75M 19.71M 36.98M 2.55B 37.17M 258M 99.33M 1.3B 100M 97.92M 4.09B	P/E 2024	-3.74x	P/E 2025	-3.65x
Enterprise Value	60.65M 0 20.01M 17.24M 16.33M 14.8M 27.76M 1.91B 27.9M 194M 74.57M 973M 75.16M 73.51M 3.07B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	77.85%	Yield 2024 *	-	Yield 2025	-

09-03	Matricelf Receives FDA Feedback Supporting Key Elements Of Proposed First In Human Clinical Trial For NewRal Spinal Cord Injury Program	CI
08-27	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-09	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study	CI
06-22	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury	CI
06-17	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant	CI
03-30	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation	CI
03-24	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury	CI
03-24	Matricelf Ltd Auditor Raises 'Going Concern' Doubt	CI
03-04	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant	CI
03-03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	CI
03-03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy	RE
02-27	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors	CI

09-03	Matricelf Receives FDA Feedback Supporting Key Elements of Proposed First in Human Clinical Trial for NewRal Spinal Cord Injury Program	PR
07-09	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones	PR
06-23	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury	AQ
03-03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy	PR
03-02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board	AQ

Matricelf Ltd Stock

Stocks

MTLF

IL0011767915

Biotechnology & Medical Research

Valuation: Matricelf Ltd

Chart: Matricelf Ltd

Latest news: Matricelf Ltd

Press Releases: Matricelf Ltd

Quotes and Performance

Price Extremes

Managers and Directors: Matricelf Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	+0.19%
1 week	-5.15%
Current month	+0.64%
1 month	-1.33%
3 months	-0.78%
6 months	-38.12%
Current year	-51.53%

1 week	260.1	289
1 month	245	316.1
Current year	212	853
1 year	212	853
3 years	204	853
5 years	204	1,555
10 years	204	1,555

Manager	Title	Age	Since
Asaf Toker CEO	Chief Executive Officer	54	01/06/2019
Tal Dvir CTO	Chief Tech/Sci/R&D Officer	51	01/06/2019
Alon Sinai COO	Chief Operating Officer	59	01/07/2019

Director	Title	Age	Since
Alon Sinai BRD	Director/Board Member	59	01/07/2019
Tal Dvir BRD	Director/Board Member	51	01/06/2019
Stanley Hirsch BRD	Director/Board Member	68	27/07/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MATRICELF LTD	+0.19%	-5.15%	-63.11%	-40.67%	26.66M
LONZA GROUP AG	+1.81%	-3.82%	-1.46%	+10.20%	45.48B
REVOLUTION MEDICINES, INC.	+0.21%	-2.98%	+337.74%	+520.30%	43.68B
IQVIA HOLDINGS INC.	+1.74%	-2.24%	+39.82%	+20.85%	43.09B
BEONE MEDICINES AG	+1.38%	-3.28%	+6.84%	+73.19%	39.4B
CELLTRION, INC.	-1.44%	-5.26%	+8.97%	+39.76%	31.91B
ASCENDIS PHARMA A/S	+0.87%	-2.60%	-	-	17.31B
MEDPACE HOLDINGS, INC.	+0.75%	-0.64%	+19.75%	+108.58%	16.4B
EUROFINS SCIENTIFIC SE	+2.83%	+1.51%	+15.22%	+31.86%	14.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.93%	-3.55%	+82.00%	+36.66%	13.28B
Average	+1.02%	-3.78%	+49.53%	+88.97%	26.48B
Weighted average by Cap.	+1.01%	-3.50%	+75.09%	+125.09%

	2024	2025
Net sales	-	-
Net income	-15.58M -0 -5.14M -4.43M -4.19M -3.8M -7.13M -491M -7.17M -49.82M -19.16M -250M -19.31M -18.89M -790M	-27.82M -0 -9.18M -7.91M -7.49M -6.79M -12.74M -877M -12.8M -88.95M -34.21M -446M -34.48M -33.72M -1.41B
Net Debt	-10.68M -0 -3.52M -3.04M -2.88M -2.61M -4.89M -337M -4.91M -34.15M -13.13M -171M -13.24M -12.94M -541M	-20.14M -0 -6.65M -5.73M -5.42M -4.91M -9.22M -635M -9.27M -64.39M -24.76M -323M -24.96M -24.41M -1.02B